title: Removal of 10-hydroxycarbazepine by plasmapheresis.
abstract: Removal of the oxcarbazepine metabolite 10-hydroxycarbazepine (MHD) by plasmapheresis was evaluated during a series of six plasmaphereses of a 13-year-old boy with Rasmussen encephalitis. Plasmapheresis was performed after steady-state concentrations of MHD had been achieved with a dose of 2550 mg oxcarbazepine daily. The mean amount of MHD removed per plasmapheresis was 78.9 mg (SD: 6.0 mg), representing 3% to 4% of the daily oxcarbazepine dose and approximately 5% to 6% of body stores of MHD. The mean steady-state trough MHD concentration was 33.3 mg/L (SD: 1.8 mg/L), and this was remarkably stable during the entire plasmapheresis period. The serum concentration of MHD was only mildly reduced by the procedure. The areas under the concentration curve of MHD on the first and sixth day of plasmapheresis were 99% and 94%, respectively, of the pre-plasmapheresis values. The results are in agreement with studies on other anticonvulsant medications (carbamazepine, valproic acid, phenobarbital, and phenytoin), indicating that minor fractions (2% to 10%) of body stores of these drugs are depleted during plasmapheresis. The authors conclude that it is unnecessary to adjust the oxcarbazepine dosage when performing single-volume plasma exchanges or even multiple exchanges during an extended period. It is further proposed that plasmapheresis is unlikely to be of therapeutic benefit in the treatment of an oxcarbazepine overdose.
authors.affiliation: Department of Clinical Pharmacology, Arhus University, Denmark. Jakob@akhphd.au.dk
authors.forename: J
authors.initials: J
authors.lastname: Christensen
authors.forename: T
authors.initials: T
authors.lastname: Balslev
authors.forename: J
authors.initials: J
authors.lastname: Villadsen
authors.forename: E M
authors.initials: EM
authors.lastname: Heinsvig
authors.forename: M
authors.initials: M
authors.lastname: Dam
authors.forename: J H
authors.initials: JH
authors.lastname: Poulsen
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000493:pharmacokinetics*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D004569:Electroencephalography; D004660:Encephalitis / Q000097:blood* / Q000628:therapy; D006801:Humans; D008297:Male; D000078330:Oxcarbazepine; D010956:Plasmapheresis / Q000379:methods*; D016896:Treatment Outcome
chemical_list: C039775:10,11-dihydro-10-hydroxycarbamazepine; D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine